Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Clinical Application of $^{18}F-FDG$ PET in Brain Tumors

뇌종양에서의 $^{18}F-FDG$ PET의 임상 이용

  • Hong, Il-Ki (Department of Nuclear Medicine, College of Medicine, Hanyang University) ;
  • Kim, Jae-Seung (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 홍일기 (한양대학교 의과대학 핵의학교실) ;
  • 김재승 (울산의대 서울아산병원 핵의학과)
  • Published : 2008.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Primary brain tumor accounts for 1.4% of entire cancer. For males between the ages of 15 and 34 years, central nervous system tumors account for the leading cause of cancer death. $^{18}F-FDG$ PET has been reported that it can provide important diagnostic information relating to tumor grading and differentiation from non- tumorous condition. In addition, the degree of FDG metabolism carries prognostic significance. By mapping the metabolic pattern of heterogeneous tumors, $^{18}F-FDG$ PET can aid in targeting for stereotactic biopsy by selecting the subregions within the tumor that are most hypermetabolic and potentially have the highest grade. According to clinical research data, FOG PET is expected to be a helpful diagnostic tool in the management of brain tumors.

Keywords